专利检索 ap:("Eli Lilly AND Company") AND inv:"BAUER, Renato A." 第 1 页

1.

发明授权
7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIT USE AS MUTANT IDH1 INHIBITORS 有权

公开(公告)号：EP3328866B1

公开(公告)日：2019-10-30

申请号：EP16745954.4

申请日：2016-07-21

申请人： Eli Lilly and Company

发明人： BAUER, Renato A. , BOULET, Serge Louis , BURKHOLDER, Timothy Paul , CARBALLARES MARTIN, Santiago , GILLIG, James Ronald , GILMOUR, Raymond , LUMERAS, Wenceslao aka LUMERAS AMADOR, Wenceslao , WU, Zhipei

IPC分类号： C07D498/04 , C07D519/00 , A61K31/5365 , A61P35/00

2.

发明授权
MUTANT IDH1 INHIBITORS 有权

公开(公告)号：EP3464281B1

公开(公告)日：2020-07-08

申请号：EP17728429.6

申请日：2017-05-30

申请人： Eli Lilly and Company

发明人： LUMERAS AMADOR, Wenceslao , BAUER, Renato A. , BOULET, Serge Louis , BURKHOLDER, Timothy Paul , GILMOUR, Raymond , HAHN, Patric James , CARBALLARES MARTIN, Santiago , RANKOVIC, Zoran

IPC分类号： C07D413/04

3.

发明公开
MUTANT IDH1 INHIBITORS 审中-公开

公开(公告)号：EP3464281A1

公开(公告)日：2019-04-10

申请号：EP17728429.6

申请日：2017-05-30

申请人： Eli Lilly and Company

发明人： LUMERAS AMADOR, Wenceslao , BAUER, Renato A. , BOULET, Serge Louis , BURKHOLDER, Timothy Paul , GILMOUR, Raymond , HAHN, Patric James , CARBALLARES MARTIN, Santiago , RANKOVIC, Zoran

IPC分类号： C07D413/04

摘要： The present application provides compounds of Formula I: Formula (I) that are useful as inhibitors of mutant IDH1, pharmaceutical compositions, and uses for the treatment of cancer.

4.

发明公开
7-PHENYLETHYLAMINO-4H-PYRIMIDO[4,5-D][1,3]OXAZIN-2-ONE COMPOUNDS AND THEIT USE AS MUTANT IDH1 INHIBITORS 审中-公开

公开(公告)号：EP3328866A1

公开(公告)日：2018-06-06

申请号：EP16745954.4

申请日：2016-07-21

申请人： Eli Lilly and Company

发明人： BAUER, Renato A. , BOULET, Serge Louis , BURKHOLDER, Timothy Paul , CARBALLARES MARTIN, Santiago , GILLIG, James Ronald , GILMOUR, Raymond , LUMERAS, Wenceslao aka LUMERAS AMADOR, Wenceslao , WU, Zhipei

IPC分类号： C07D498/04 , C07D519/00 , A61K31/5365 , A61P35/00

摘要： Phenylethylamino-4H-pyrimido[4,5-d][1,3]oxazin-2-one compounds of Formula I, formulations containing those compounds, and their use as mutant isocitrate dehydrogenase 1 enzyme inhibitors.